Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors
Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors
复制标题
DOI：
10.1007/s10549-007-9683-8
复制
发表时间：
2008-06-01
影响因子：
3.8
通讯作者：
Caan, Bette
中科院分区：
文献类型：
--
作者：
Kwan, Marilyn L.;Habel, Laurel A.;Caan, Bette
目的研究诊断后应用他汀类药物(3-羟基-3-甲基戊二酰辅酶A[HMG-CoA]抑制剂)与乳腺癌复发风险的关系。材料与方法1945名早期乳腺癌幸存者参加了癌症后生活流行病学(LACE)研究。从1997年到2000年被确诊并从北加州凯撒永久癌症登记中心(KPNC)确诊的女性平均在确诊后2年进入队列。有关他汀类药物使用的信息从KPNC药房数据库中获得。总共报告了210例乳腺癌复发，并通过病历复查进行了验证。结果在诊断后开始使用他汀类药物的患者中，他汀类药物的平均使用年限为1.96年，主要使用亲脂性他汀类药物(97.8%)。确诊后开始服用他汀类药物提示乳腺癌复发风险降低(RR=0.67；95%CI：0.39-1.13)。随着诊断后他汀类药物使用时间的增加，复发风险降低(p线性趋势=0.02)。结论我们的研究结果初步支持了诊断后、脂溶性他汀类药物的使用与乳腺癌复发风险之间的负相关。
Purpose We examined the association between post-diagnosis statin use (3-hydroxy-3-methylglutaryl-coenzyme A [HMG-CoA] inhibitors) and risk of breast cancer recurrence.Materials and methods The study included 1945 early stage breast cancer survivors participating in the Life After Cancer Epidemiology (LACE) Study. Women who were diagnosed from 1997 to 2000 and identified from the Kaiser Permanente Northern California (KPNC) Cancer Registry entered the cohort on average 2 years post-diagnosis. Information on statin use was obtained from the KPNC pharmacy database. A total of 210 breast cancer recurrences were reported and verified by medical record review. Cox proportional hazard models were used to estimate rate ratios (RR) and 95% confidence intervals (CI).Results The mean duration of statin use in the cohort among those who initiated use post-diagnosis was 1.96 years, and lipophilic statins were mainly used (97.8%). Starting statins after diagnosis was suggestive of a decreased risk of breast cancer recurrence (RR = 0.67; 95% CI: 0.39-1.13). Risk of recurrence decreased with increasing duration of statin use after diagnosis (p linear trend = 0.02).Conclusion Our findings provide initial support for an inverse association between post-diagnosis, lipophilic statin use and risk of breast cancer recurrence.